Full Text Journal Articles by
Author Jo Anne Vergilio

Advertisement

Find full text journal articles






Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.

Len Rosenberg, Hugh Levaux, Ross L Levine, Amit Shah, James Denmark, Nyla Hereema, Melanie Owen, Spencer Kalk, Nicholas Kenny, Gene Vinson, Jo-Anne Vergilio, Alice Mims, Uma Borate, William Blum, Eytan Stein, Theophilus J Gana, Mona Stefanos, Ashley Yocum, Sonja Marcus, Abigail Shoben, Brian Druker, John Byrd, Amy Burd,

Advances in genomic technologies and an increased understanding of the molecular pathogenesis of cancer have resulted in development of new effective, mutation-targeted therapies. In turn, these informed the development of Master Trial designs to test these therapies. The Beat Acute Myeloid Leukemia (BAML) Master Trial (Sponsor: The Leukemia & Lymphoma ... Read more >>

Ther Innov Regul Sci (Therapeutic innovation & regulatory science)
[2021, :]

Cited: 0 times

View full text PDF listing >>



JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.

Megan J Fitzpatrick, Lucas R Massoth, Chelsea Marcus, Jo-Anne Vergilio, Eric Severson, Daniel Duncan, Shakti H Ramkissoon, Robert P Hasserjian, Annette S Kim, Aliyah R Sohani, Erik A Williams, Valentina Nardi,

Peripheral T-cell lymphoma (PTCL) comprises a heterogenous group of rare mature T-cell neoplasms. While some PTCL subtypes are well-characterized by histology, immunophenotype, and recurrent molecular alterations, others remain incompletely defined. In particular, the distinction between CD30+ PTCL, not otherwise specified and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma can ... Read more >>

Am J Surg Pathol (The American journal of surgical pathology)
[2021, 45(7):895-904]

Cited: 0 times

View full text PDF listing >>



Advertisement

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.

Lucas R Massoth, Yin P Hung, Judith A Ferry, Robert P Hasserjian, Valentina Nardi, G Petur Nielsen, Sam Sadigh, Vinayak Venkataraman, Martin Selig, Alison M Friedmann, Wesley Samore, Jonathan Keith Killian, Riza Milante, Joseph Giessinger, Kathleen Foley-Peres, Chelsea Marcus, Eric Severson, Daniel Duncan, Smruthy Sivakumar, Jeffrey S Ross, Vikram Desphande, Shakti H Ramkissoon, Jo-Anne Vergilio, Abner Louissaint, Lawrence R Zukerberg, Erik A Williams,

<h4>Background</h4>Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim-Chester disease have been well described, other less common and often aggressive tumors in this broad category remain poorly characterized, and comparison studies ... Read more >>

Oncologist (The oncologist)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.

Gennady Bratslavsky, Stephanie Gleicher, Joseph M Jacob, Thomas H Sanford, Oleg Shapiro, Dimitra Bourboulia, Laurie M Gay, Julie Andrea Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Eric Allan Severson, Jonathan Keith Killian, Alexa Betzig Schrock, Jon H Chung, Vincent A Miller, Mehdi Mollapour, Jeffrey S Ross,

<h4>Introduction and objective</h4>Unlike clear cell renal cell carcinoma (CCRCC), collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are rare tumors that progress rapidly and appear resistant to current systemic therapies. We queried comprehensive genomic profiling to uncover opportunities for targeted therapy and immunotherapy.<h4>Material and methods</h4>DNA was extracted from 40 ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(6):367.e1-367.e5]

Cited: 0 times

View full text PDF listing >>



Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.

Amy Burd, Ross L Levine, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Prapti Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary Schiller, Rebecca Olin, Mark Litzow, James Foran, Tara L Lin, Brian Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha Arellano, Alison Walker, Vu H Duong, Tibor Kovacsovics, Robert Collins, Abigail B Shoben, Nyla A Heerema, Matthew C Foster, Jo-Anne Vergilio, Tim Brennan, Christine Vietz, Eric Severson, Molly Miller, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Timothy Chen, Mona Stefanos, Brian Druker, John C Byrd,

Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome<sup>1,2</sup>. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile ... Read more >>

Nat Med (Nature medicine)
[2020, 26(12):1852-1858]

Cited: 2 times

View full text PDF listing >>



Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.

Douglas I Lin, Nikunj Shah, Julie Y Tse, Jonathan K Killian, Amanda Hemmerich, Claire Edgerly, James Haberberger, Eric A Severson, Richard S P Huang, Shakti H Ramkissoon, Jo-Anne Vergilio, Jeffrey S Ross, Julia A Elvin,

Mesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) ... Read more >>

Gynecol Oncol Rep (Gynecologic oncology reports)
[2020, 34:100652]

Cited: 1 time

View full text PDF listing >>



A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.

Richard S P Huang, James Haberberger, Eric Severson, Daniel L Duncan, Amanda Hemmerich, Claire Edgerly, Naomi Lynn Ferguson, Erik Williams, Julia Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas I Lin, Julie Tse, Matthew Hiemenz, Clarence Owens, Natalie Danziger, Priti S Hegde, Jeffrey Venstrom, Brian Alexander, Jeffrey S Ross, Shakti H Ramkissoon,

PD-L1 immunohistochemistry (IHC) currently has the most Food and Drug Administration (FDA) approvals as a companion diagnostic (CDx) for immunotherapies in specific tumor types; however, multiple other immunotherapy biomarkers exist. We performed this study to examine and report the prevalence of PD-L1 expression in a wide variety of tumor types ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2021, 34(2):252-263]

Cited: 4 times

View full text PDF listing >>



Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.

Andrew Rankin, Adrienne Johnson, Alison Roos, Geoffrey Kannan, Jeffrey Knipstein, Nicholas Britt, Mark Rosenzweig, James Haberberger, Dean Pavlick, Eric Severson, Jo-Anne Vergilio, Rachel Squillace, Rachel Erlich, Pratheesh Sathyan, Stuart Cramer, David Kram, Jeffrey Ross, Vince Miller, Prasanth Reddy, Brian Alexander, Siraj M Ali, Shakti Ramkissoon,

RAF family protein kinases signal through the MAPK pathway to orchestrate cellular proliferation, survival, and transformation. Identifying BRAF alterations in pediatric cancers is critically important as therapeutic agents targeting BRAF or MEK may be incorporated into the clinical management of these patients. In this study, we performed comprehensive genomic profiling ... Read more >>

Oncologist (The oncologist)
[2021, 26(1):e153-e163]

Cited: 0 times

View full text PDF listing >>



Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.

Richard S P Huang, Xinyan Li, James Haberberger, Ethan Sokol, Eric Severson, Daniel L Duncan, Amanda Hemmerich, Claire Edgerly, Erik Williams, Julia Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas Lin, Matthew Hiemenz, Jinpeng Xiao, Deborah McEwan, Oliver Holmes, Natalie Danziger, Rachel Erlich, Garrett Frampton, Michael B Cohen, Kimberly McGregor, Prasanth Reddy, Dawn Cardeiro, Rachel Anhorn, Jeffrey Venstrom, Brian Alexander, Charlotte Brown, Lajos Pusztai, Jeffrey S Ross, Shakti H Ramkissoon,

<h4>Background</h4>We examined the current biomarker landscape in breast cancer when programmed death-ligand 1 (PD-L1) testing is integrated with comprehensive genomic profiling (CGP).<h4>Material and methods</h4>We analyzed data from samples of 312 consecutive patients with breast carcinoma tested with both CGP and PD-L1 (SP142) immunohistochemistry (IHC) during routine clinical care. These samples ... Read more >>

Oncologist (The oncologist)
[2020, 25(11):943-953]

Cited: 2 times

View full text PDF listing >>



Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.

Lucas R Massoth, Yin P Hung, Valentina Nardi, G Petur Nielsen, Robert P Hasserjian, Abner Louissaint, Adam S Fisch, Vikram Deshpande, Lawrence R Zukerberg, Jochen K Lennerz, Martin Selig, Krzysztof Glomski, Parth J Patel, Kevin Jon Williams, Ethan S Sokol, Brian M Alexander, Jo-Anne Vergilio, Jeffrey S Ross, Dean C Pavlick, Ivan Chebib, Erik A Williams,

Sarcomas are driven by diverse pathogenic mechanisms, including gene rearrangements in a subset of cases. Rare soft tissue sarcomas containing KMT2A fusions have recently been reported, characterized by a predilection for young adults, sclerosing epithelioid fibrosarcoma-like morphology, and an often aggressive course. Nonetheless, clinicopathologic and molecular descriptions of KMT2A-rearranged sarcomas ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2020, 33(11):2307-2317]

Cited: 3 times

View full text PDF listing >>



Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.

Lucas R Massoth, Yin P Hung, Dora Dias-Santagata, Maristela Onozato, Nikunj Shah, Eric Severson, Daniel Duncan, Brendan J Gillespie, Nathan F Williams, Jeffrey S Ross, Jo-Anne Vergilio, Shannon K Harkins, Krzysztof Glomski, Valentina Nardi, Lawrence R Zukerberg, Robert P Hasserjian, Abner Louissaint, Erik A Williams,

<h4>Purpose</h4>Thymomas are epithelial neoplasms that represent the most common thymic tumors in adults. These tumors have been shown to harbor a relatively low mutational burden. As a result, there is a lack of genetic alterations that may be used prognostically or targeted therapeutically for this disease. Here, we describe a ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2020, 4:]

Cited: 3 times

View full text PDF listing >>



Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens.

Margaret A Hay, Eric A Severson, Vincent A Miller, David A Liebner, Jo-Anne Vergilio, Sherri Z Millis, James L Chen,

<h4>Purpose</h4>Comprehensive genomic profiling (CGP) of sarcomas is rapidly being integrated into routine clinical care to help refine diagnosis and prognosis and determine treatment. However, little is known about barriers to successful CGP or its clinical utility in sarcoma. We set out to determine whether CGP alters physician treatment decision-making, and ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2020, 4:]

Cited: 0 times

View full text PDF listing >>



Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.

Douglas I Lin, Amanda Hemmerich, Claire Edgerly, Daniel Duncan, Eric A Severson, Richard S P Huang, Shakti H Ramkissoon, Yamicia D Connor, Meghan Shea, Jonathan L Hecht, Siraj M Ali, Jo-Anne Vergilio, Jeffrey S Ross, Julia A Elvin,

OBJECTIVE:Genomic alterations of BCOR via ZC3H7B-BCOR fusion or BCOR internal tandem duplication (ITD) define a subset of endometrial stromal sarcoma (ESS). The goals of this study were to: 1) determine the molecular landscape of BCOR-rearranged ESS, 2) to identify novel BCOR fusion gene partners in ESS and their associated clinicopathological ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2020, 157(2):357-366]

Cited: 3 times

View full text PDF listing >>



Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.

Andrea Necchi, Russell Madison, Daniele Raggi, Joseph M Jacob, Gennady Bratslavsky, Oleg Shapiro, Julia A Elvin, Jo-Anne Vergilio, Jonathan K Killian, Nhu Ngo, Shakti Ramkissoon, Eric Severson, Amanda C Hemmerich, Richard Huang, Siraj M Ali, Jon H Chung, Prasanth Reddy, Vincent A Miller, Alexa B Schrock, Laurie M Gay, Brian M Alexander, Petros Grivas, Jeffrey S Ross,

<h4>Background</h4>In patients with rare histologies of bladder cancer, including adenocarcinoma of the bladder (ACB) and squamous-cell carcinoma (SCC), there are limited standard therapy options, defining an unmet medical need.<h4>Objective</h4>In this comparative comprehensive genomic profiling (CGP) study, genomic alterations (GAs), and immuno-oncology (IO) biomarkers have been analyzed.<h4>Design, setting, and participants</h4>Within the ... Read more >>

Eur Urol (European urology)
[2020, 77(4):548-556]

Cited: 9 times

View full text PDF listing >>



Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Andrea Necchi, Gennady Bratslavsky, Oleg Shapiro, Julia A Elvin, Jo-Anne Vergilio, Jonathan K Killian, Nhu Ngo, Shakti Ramkissoon, Eric Severson, Amanda C Hemmerich, Siraj M Ali, Jon H Chung, Prasanth Reddy, Vincent A Miller, Alexa B Schrock, Laurie M Gay, Jeffrey S Ross, Joseph M Jacob,

<h4>Background</h4>Metastatic testicular sex cord stromal tumors of the testis (MSCSTs) comprise an extremely uncommon form of genitourinary malignancy.<h4>Objective</h4>To perform comprehensive genomic profiling (CGP) to enable the search for potential therapy targets.<h4>Design, setting, and participants</h4>Ten patients with testicular Leydig cell tumors (LCTs), six with Sertoli cell tumors (SCTs), and three with ... Read more >>

Eur Urol Focus (European urology focus)
[2019, 5(5):748-755]

Cited: 3 times

View full text PDF listing >>



SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Douglas I Lin, Justin M Allen, Jonathan L Hecht, Jonathan K Killian, Nhu T Ngo, Claire Edgerly, Eric A Severson, Siraj M Ali, Rachel L Erlich, Shakti H Ramkissoon, Jo-Anne Vergilio, Jeffrey S Ross, Julia A Elvin,

A rare subset of aggressive SMARCA4-deficient uterine sarcomas has been recently proposed, with only a limited number of cases having been previously described. Here, we identify 16 additional cases of SMARCA4-deficient uterine sarcoma from the database of a large, CLIA-certified and CAP-accredited, reference molecular laboratory, and we expand on their ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2019, 32(11):1675-1687]

Cited: 7 times

View full text PDF listing >>



Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Natalie Galanina, Rafael Bejar, Michael Choi, Aaron Goodman, Matthew Wieduwilt, Carolyn Mulroney, Lisa Kim, Huwate Yeerna, Pablo Tamayo, Jo-Anne Vergilio, Tariq I Mughal, Vincent Miller, Catriona Jamieson, Razelle Kurzrock,

<i>Background</i>: The translation of genomic discoveries to the clinic is the cornerstone of precision medicine. However, incorporating next generation sequencing (NGS) of hematologic malignancies into clinical management remains limited. <i>Methods</i>: We describe 235 patients who underwent integrated NGS profiling (406 genes) and analyze the alterations and their potential actionability. <i>Results</i>: ... Read more >>

Cancers (Basel) (Cancers)
[2018, 11(1):]

Cited: 5 times

View full text PDF listing >>



Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.

Joseph M Jacob, Elizabeth K Ferry, Laurie M Gay, Julia A Elvin, Jo-Anne Vergilio, Shakti Ramkissoon, Eric Severson, Andrea Necchi, J Keith Killian, Siraj M Ali, Alexa B Schrock, Nick W Liu, J Chung, V A Miller, P J Stephens, A Welsh, Robert J Corona, Jeffrey S Ross, Gennady Bratslavsky,

<h4>Purpose</h4>Metastatic penile squamous cell carcinoma is an aggressive malignancy with limited treatment options. We compared the potential therapy impacting genomic alterations between metastatic penile squamous cell carcinoma and nonpenile metastatic cutaneous squamous cell carcinoma.<h4>Materials and methods</h4>DNA was extracted from 40 μ of formalin fixed, paraffin embedded samples from 78 cases ... Read more >>

J Urol (The Journal of urology)
[2019, 201(3):541-548]

Cited: 6 times

View full text PDF listing >>



Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.

Andrea Necchi, Gennady Bratslavsky, Robert J Corona, Jon H Chung, Sherri Z Millis, Julia A Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Eric Severson, Sugganth Daniel, Jonathan K Killian, Siraj M Ali, Alexa B Schrock, Prasanth Reddy, Vincent A Miller, Allison Welsh, Laurie M Gay, Jeffrey S Ross,

<h4>Background</h4>Although both seminomatous and nonseminomatous testicular germ cell tumors (TGCTs) have favorable outcomes with chemotherapy, a subset is chemorefractory, and novel therapeutic options are needed.<h4>Objective</h4>To molecularly characterize chemotherapy-refractory TGCTs.<h4>Design, setting, and participants</h4>Archival tissues from 107 chemotherapy-treated and relapsed TGCT patients (23 seminomas; 84 nonseminomas) underwent hybrid-capture-based genomic profiling to evaluate ... Read more >>

Eur Urol Focus (European urology focus)
[2020, 6(1):122-130]

Cited: 7 times

View full text PDF listing >>



Genomic Landscape of Adult and Pediatric BCR-ABL1-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing.

Eric A Severson, Jo-Anne Vergilio, Laurie M Gay, Sugganth Daniel, Amanda C Hemmerich, Julia A Elvin, Nicholas Britt, Michelle Nahas, Michael B Cohen, Charlotte Brown, Pratheesh Sathyan, Andrew Rankin, Vincent Miller, Jeffrey S Ross, Shakti H Ramkissoon,

BCR-ABL1-like B-Acute Lymphoblastic Leukemia (B-ALL) is a subset of B-ALL with a poor prognosis that is found in all age groups. Definitive identification of these patients is difficult in routine clinical practice as gene expression profiling, the gold standard test, is not widely available. Comprehensive genomic profiling performed on 450 ... Read more >>

Oncologist (The oncologist)
[2019, 24(3):372-374]

Cited: 1 time

View full text PDF listing >>



Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, Helen J Huang, Yasuhiro Oki, Ignacio Garrido-Laguna, Haeseong Park, Jason R Westin, Funda Meric-Bernstam, David Fabrizio, Vincent A Miller, Philip J Stephens, Michelle A Fanale, Jeffrey S Ross, Filip Janku,

<h4>Background</h4>The genomic landscape of Hodgkin lymphoma (HL) has been difficult to characterize due to the paucity of neoplastic cells and an abundant microenvironment. Such characterization is needed in order to improve treatment strategies.<h4>Materials and methods</h4>We performed comprehensive genomic profiling (CGP) using targeted next-generation sequencing on archival formalin-fixed paraffin embedded tumor ... Read more >>

Oncologist (The oncologist)
[2019, 24(2):219-228]

Cited: 10 times

View full text PDF listing >>



Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

Eric A Severson, Gregory M Riedlinger, Caitlin F Connelly, Jo-Anne Vergilio, Mendel Goldfinger, Shakti Ramkissoon, Garrett M Frampton, Jeffrey S Ross, Anthony Fratella-Calabrese, Laurie Gay, Siraj Ali, Vincent Miller, Julia Elvin, Mohammad Hadigol, Kim M Hirshfield, Lorna Rodriguez-Rodriguez, Shridar Ganesan, Hossein Khiabanian,

Blood (Blood)
[2018, 131(22):2501-2505]

Cited: 12 times

View full text PDF listing >>



Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

James H Suh, Alexa B Schrock, Adrienne Johnson, Doron Lipson, Laurie M Gay, Shakti Ramkissoon, Jo-Anne Vergilio, Julia A Elvin, Abdur Shakir, Peter Ruehlman, Karen L Reckamp, Sai-Hong Ignatius Ou, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali,

BACKGROUND:In our recent study, of cases positive for epidermal growth factor receptor (EGFR) exon 19 deletions using comprehensive genomic profiling (CGP), 17/77 (22%) patients with prior standard of care (SOC) EGFR testing results available were previously negative for exon 19 deletion. Our aim was to compare the detection rates of ... Read more >>

Oncologist (The oncologist)
[2018, 23(7):776-781]

Cited: 2 times

View full text PDF listing >>



PATH-38. COMPREHENSIVE GENOMIC PROFILING OF OLIGODENDROGLIOMAS REFINES TUMOR DIAGNOSES AND IDENTIFIES PATIENTS FOR TARGETED THERAPIES AND IMMUNE CHECKPOINT INHIBITORS

Shakti Ramkissoon, Lee Albacker, Eric Severson, Caitlin Connelly, Adrienne Johnson, Laurie Gay, Jo-Anne Vergilio, Julia Elvin, James Suh, Sugganth Daniel, Charlotte Brown, Mandy Covert, Alexa Schrock, Garrett Frampton, Siraj Ali, Philip Stephens, Vincent Miller, Jeffrey Ross,

Abstract BACKGROUND Oligodendrogliomas (ODG) are diffusely infiltrating gliomas characterized by IDH mutations and 1p/19q co-deletion. Distinguishing between diffuse gliomas can be challenging based solely on microscopic features and lead to misclassification of glioma lineage. Genomic profiling of oligodendrogliomas is critical to ensuring diagnostic accuracy and identifying therapeutic options for patients ... Read more >>

Neuro Oncol (Neuro-oncology)
[2017, 19(Suppl 6):vi179-vi179]

Cited: 0 times

View full text PDF listing >>



PATH-20. COMPREHENSIVE GENOMIC PROFILING COMPARING PRIMARY CNS LYMPHOMA TO SYSTEMIC DIFFUSE LARGE B CELL LYMPHOMA REVEALS BIOMARKERS INDICATING POTENTIAL BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS

Eric Severson, Jo-Anne Vergilio, Laurie Gay, Sugganth Daniel, Julia Elvin, James Suh, Mandy Covert, Charlotte Brown, Vincent Miller, Philip Stephens, Jeffrey Ross, Shakti Ramkissoon,

Abstract BACKGROUND B-Cell Primary CNS Lymphoma (PCL) is Diffuse Large B-cell Lymphoma (DLBCL) confined to the CNS. Less than 50% of PCL patients achieve complete remission with current therapies. Comprehensive genomic profiling (CGP) may suggest novel treatment modalities including use of immune checkpoint inhibitors (ICPI). DESIGN: 24 cases of B-cell ... Read more >>

Neuro Oncol (Neuro-oncology)
[2017, 19(Suppl 6):vi175-vi175]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.9131 s